Overview

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Status:
Recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with relapsed or refractory PCNSL

Phase:

Phase 2

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd